Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J.P. Morgan Day Four: Roche Sees Lots Of Partnering Interest, While Bluebird, Sage Offer Launch Updates

11 Jan 2024

• By Scrip Team

J.P. Morgan 2024 — • Source: Shutterstock

Related Content

ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

16 Feb 2023

Vir Biotechnology Decreases The Surplus Population

14 Dec 2023

Vertex/CRISPR Nab First-Ever Gene Editing FDA Nod, Overshadow Bluebird’s Same-Day Win

09 Dec 2023

Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress

08 Nov 2023

Madrigal Shows Confidence As It Awaits FDA’s March Decision On Resmetirom

13 Nov 2023

Finance Watch: J.P. Morgan Conference To Offer Glimpse Of 2024 Funding Forecast

05 Jan 2024

Related Companies

Madrigal Pharmaceuticals, Inc.

Roche Holding AG

Vir Biotechnology, Inc.

Sage Therapeutics, Inc.

Biogen, Inc.

Bluebird Bio

Additional Topics

Deals M & A Launches Growth Reimbursement Strategy Commercial BioPharmaceutical

More from Deals

More from Conferences

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.